Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 02, 2020
Evofem Biosciences has announced pricing of an underwritten public offering of 28.5 million shares of its common stock at a price of $3.50/share. The gross proceeds are expected to be approximately $100 million. Evofem is committed to develop innovation women's healthcare product.